Slate Path Capital LP 13D and 13G filings for Cue Biopharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 5:00 pm Sale | 2024-12-31 | 13G | Cue Biopharma, Inc. CUE | Slate Path Capital LP | 918,836 1.400% | -1,483,619 (-61.75%) | Filing |
| 2023-02-14 09:30 am Unchanged | 2022-12-31 | 13G | Cue Biopharma, Inc. CUE | Slate Path Capital LP | 2,402,455 5.600% | 0 (Unchanged) | Filing |
| 2022-11-18 4:04 pm Purchase | 2022-11-16 | 13G | Cue Biopharma, Inc. CUE | Slate Path Capital LP | 2,402,455 5.600% | 2,402,455 (New Position) | Filing |